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Impact of body fat changes in mediating
the effects of antiretroviral therapy on
blood pressure in HIV-infected persons in a
sub-Saharan African setting
Chidozie U. Nduka1*, Olalekan A. Uthman2,3, Peter K. Kimani1, Abraham O. Malu4 and Saverio Stranges1,5
Abstract
Background: Previous studies of HIV-infected patients have shown significant associations between highly active
antiretroviral therapy (HAART) and increased blood pressure; however, the mechanisms involved are less clear.
Therefore, we sought to investigate the potential impact of body fat changes in mediating the effects of HAART on
blood pressure changes among people living with HIV.
Methods: Four hundred six consenting patients (≥18 years of age) attending a tertiary HIV clinic in semi-urban
Nigeria were recruited between August and November 2014 as part of a cross-sectional study. We performed
bias-corrected bootstrap tests of mediation using 95 % confidence intervals (CI) to determine the mediating effects
of body mass index and waist circumference (mediators) on the total effects of HAART exposure (primary predictor)
on blood pressure (outcome), while controlling for age, sex and other potential confounders.
Results: Waist circumference remained a significant partial mediator of the total effects of HAART exposure on
increasing systolic blood pressure (coefficient: 1.01, 95 % CI: 0.33 to 2.52, 11 % mediated) and diastolic blood
pressure (coefficient: 0.68, 95 % CI: 0.26 to 1.89, 9 % mediated) after adjusting for age, sex, smoking status, CD4
count and duration of HIV infection. No significant mediating effect was observed with body mass index alone or
in combination with waist circumference after adjusting for all potential confounders.
Conclusion: Waist circumference significantly mediates the effects of HAART on blood pressure in persons living
with HIV, independent of the role of traditional risk factors. The use of waist circumference as a complementary
body fat measure to body mass index may improve the clinical prediction of hypertension in HIV-infected patients
on antiretroviral therapy.
Keywords: Highly active antiretroviral therapy, Waist circumference, Body mass index, Blood pressure, HIV, Mediate
Multilingual abstracts
Please see Additional file 1 for translation of the ab-
stracts into the six official working languages of the
United Nations.
Background
Antiretroviral drugs increase blood pressure by damaging
the endothelial linings of blood vessels, which in turn
interferes with the production of biological markers known
to regulate blood pressure [1–3]. Nonetheless, alternative
mediating mechanisms may partially account for the effects
of antiretroviral therapy on blood pressure. For instance,
antiretroviral drugs, such as the reverse transcriptase inhibi-
tors and protease inhibitors, may be associated with
changes in body fat measures [4, 5], which in turn may be
associated with increased blood pressure [6–8]. However,
the biological mechanisms of these associations remain
unclear.
Studies evaluating the impact of antiretroviral therapy
on blood pressure changes have usually controlled for
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measures of relative weight (such as body mass index)
and body fat distribution (such as waist circumference)
using multiple regression models: blood pressure is
linearly regressed on antiretroviral status while adjusting
for body mass index or waist circumference [9–11].
However, covariate adjustments using regression ana-
lyses do not account for the direction of association or
the mechanisms through which blood pressure changes
may occur following antiretroviral treatment. Therefore,
we sought to examine whether the effects of antiretro-
viral therapy on blood pressure may be mediated by dif-
ferent measures of body fat, notably body mass index
and waist circumference, in people living with HIV.
Assessing these alternative causal pathways could be
useful in uncovering the complex epidemiology of
hypertension and other cardio-metabolic disorders
among people living with HIV, especially in sub-Saharan
African settings, where the burden of HIV infection is
highest and the increase in antiretroviral coverage is the
steepest in the world [12].
Methods
Study design and setting
Consenting HIV-infected patients attending the HIV
clinic at the Benue State University Teaching Hospital
(BSUTH) in Nigeria were recruited between August and
November 2014 as part of a cross-sectional study. The
HIV clinic at BSUTH is one of two tertiary HIV clinics
in Benue state, with approximately 30 patients in weekly
attendance. Until two years ago, Benue had consistently
recorded the highest prevalence of HIV across all states
in Nigeria, accounting for more than 10 % of its resident
population throughout the preceding decade [13]. The
current prevalence estimate of HIV in Benue now stands
at 5.6 %, which remains substantially higher than the
national average of 3.3 % [13].
Participants
HIV-infected patients who were no less than 18 years
old, naïve or exposed to HAART and able to communi-
cate in English or Nigerian pidgin were included in the
study. We sampled consecutive patients until we had
recruited 406 participants, comprising 306 patients
exposed to HAART and 100 HAART-naïve patients.
HIV-infected patients who were less than 18 years old,
pregnant and lactating mothers, persons in the advanced
clinical stages of HIV infection (patients diagnosed with
opportunistic infections or AIDS-defining illnesses), pa-
tients diagnosed with antiretroviral treatment failure and
those with CD4 cell counts that had been assessed more
than three months prior to the commencement of the
study were considered ineligible for inclusion in the
study.
Study protocol
Figure 1 illustrates the hypothesized mediation pathways.
The primary predictor was highly active antiretroviral
therapy (HAART), which was defined as treatment using
Fig. 1 Hypothesized causal pathways explaining the effects of antiretroviral therapy (HAART) on blood pressure
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two nucleoside reverse transcriptase inhibitors with either
one non-nucleoside reverse transcriptase inhibitor
(2NRTI + 1NNRTI) or one protease inhibitor (2NRTI +
1PI). On the other hand, patients were naïve to HAART if
they had not commenced antiretroviral therapy. Body
mass index and waist circumference were the mediators,
and the outcomes included systolic blood pressure, dia-
stolic blood pressure and random blood glucose levels. To
adjust for potential confounding effects of the mediators,
we obtained data on the traditional risk factors of high
blood pressure (such as age, sex and smoking status), and
HIV-related factors, including CD4 cell count and dur-
ation of HIV infection. Data on HAART status, CD4 cell
counts and duration of HIV infection were obtained from
the patients’ medical records. Body mass index and waist
circumference were measured using standard protocols
[14]. Blood pressure was measured using the Omron M10
IT Blood Pressure Monitor. The average of the first two
blood pressure readings taken no less than 20 min apart
was recorded as the patient’s blood pressure. A third
blood pressure reading was taken in cases where the dis-
parity was substantial (≥5 mmHg) between the first two
systolic or diastolic blood pressure readings [15, 16]. All
data measurements were validated and obtained similarly
from all participants.
Statistical analysis
For descriptive purposes, we summarized the distribution
of the variables according to HAART status. The values
were expressed as mean ± standard deviation for continu-
ous variables and absolute numbers (percentages) for cat-
egorical variables. We stratified the association between
body mass index/waist circumference and systolic/dia-
stolic blood pressure by HAART status to rule out
HAART status as an effect modifier. To investigate the
potential impact of body mass index in mediating the ef-
fects of HAART on systolic and diastolic blood pressure,
we estimated the mediation coefficients by fitting linear
regression models following the steps outlined by Baron
and Kenny: [17] in the first step, body mass index was
regressed on HAART status; in the second step, systolic
and diastolic blood pressure were each regressed on
HAART status; in the third step, systolic and diastolic
blood pressure were each regressed on body mass index
while adjusting for HAART status. Using the mediation
coefficients, we estimated the indirect effects (Path AB) of
HAART exposure on systolic and diastolic blood pressure
through body mass index. We also computed the direct
effects (Path C’) of HAART exposure on systolic and
diastolic blood pressure. The proportions of the total ef-
fects of HAART exposure on systolic and diastolic blood
pressure that were mediated by body mass index were
obtained by computing the ratios of the indirect effects to
the sum of the direct and indirect effects. We
subsequently controlled the mediating effects of body
mass index for age, sex, smoking status, CD4 cell count
and duration of HIV infection. These analyses were re-
peated to estimate the unadjusted and covariate-adjusted
mediating effects of waist circumference and combined
body mass index/waist circumference on the associations
between HAART and blood pressure. Bias-corrected boot-
strap tests of mediation were subsequently performed
using 500 replications to determine whether the mediating
effects were statistically significant using 95 % confidence
intervals [18, 19]. This study is reported according to the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement (See Additional file 2).
Sample size
The sample size calculation to evaluate mediation ana-
lysis for a linear model was given by the following equa-
tion: [20]
n ¼ L
f 2
þ k þ 1
where n denotes the sample size; L is equal to 7.85,
which is the linear statistic corresponding to ordinary
least squares (OLS) regression for one predictor with a
type I error of 0.05 and power of 0.8; k is equal to 1,
which is the number of predictors in the OLS regression;
and f is the coefficient of the regression equation corre-
sponding to the indirect effect (Path AB) of the predictor
variable on the outcome variable, through the mediator.
Assuming that the coefficients for Path A (0.14) and
Path B (0.14) are small according to Cohen’s criteria for
small effect sizes [20, 21], the indirect effect (Path AB)
would entail the product of the coefficients A and B (i.e.,
0.0196).
Therefore, using these default values, we aimed for a
sample size of 403.
Ethical considerations
Patients in advanced clinical stages of HIV infection, such
as those with opportunistic infections or other AIDS-
defining illnesses, were considered particularly vulnerable
and excluded from the study. Ethical approval was obtained
from the BSUTH Health Research Ethics Committee in
Nigeria (NHREC/08/11/2013B), and the University of
Warwick Biomedical Science Research Ethics Committee,
United Kingdom (REGO-2014-711). All patients provided
written informed consent prior to participation.
Results
Table 1 summarizes the socio-demographic and clin-
ical characteristics of the study population by
HAART status. In total, 406 HIV-infected patients,
comprising 306 HAART-exposed and 100 HAART-
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naïve subjects participated in the study. Body mass
index (P < 0.05) and waist circumference (P < 0.0001)
were significantly higher among HAART-exposed
patients compared with HAART-naïve patients. Sys-
tolic and diastolic blood pressure levels were also
significantly higher among HAART-exposed patients
(P < 0.0001 for each). As shown in Table 2, the asso-
ciations of body mass index and waist circumference
with systolic and diastolic blood pressure were direct
and statistically significant overall (P < 0.0001 for
each), in HAART-exposed (P < 0.0001 for each), and
HAART-naïve patients (P < 0.0001 for each).
Table 1 Characteristics of the study population by HAART status
Characteristics Total
(N = 406)
HAART-exposed (N = 306) HAART-naïve (N = 100)
Gender
Female, n (%) 278 (68.5) 200 (65.4) 78 (78.0)*
Male, n (%) 128 (31.5) 106 (34.6) 22 (22.0)
Age (years), mean ± SD 37.6 ± 11.2 38.6 ± 10.0 35.6 ± 12.5*
18–40 years, n (%) 264 (66.0) 189 (62.6) 75 (76.5)
41–64 years, n (%) 128 (32.0) 108 (35.8) 20 (20.4)
≥ 65 years, n (%) 8 (2.0) 5 (1.6) 3 (3.1)
Smoking status, n (%)
Never smokers 354 (89.4) 266 (89.3) 88 (89.8)
Ever smokers 42 (10.6) 32 (10.7) 10 (10.2)
Weight (kg), mean ± SD 65.8 ± 12.8 65.6 ± 11.6 60.2 ± 12.4**
Height (cm), mean ± SD 163.1 ± 8.4 163.7 ± 8.7 160.3 ± 7.6***
BMI (kg/m2), mean ± SD 24.7 ± 4.6 24.5 ± 4.4 23.4 ± 4.3*
< 25 kg/m2, n (%) 245 (62.7) 175 (59.7) 70 (71.4)
≥ 25 kg/m2, n (%) 146 (37.3) 118 (40.3) 28 (28.6)
WC (cm), mean ± SD 85.9 ± 11.6 86.3 ± 10.3 82.9 ± 12.2**
CD4 count (cells/mm3), mean ± SD 454.1 ± 250.5 439.8 ± 255.5 504.1 ± 226.7***
< 500 cells/mm3, n (%) 252 (65.3) 200 (66.7) 52 (60.5)
≥ 500 cells/mm3, n (%) 134 (34.7) 100 (33.3) 34 (39.5)
HIV duration (months), mean ± SD 45.0 ± 29.4 50.2 ± 29.3 29.0 ± 22.8****
< 24 months, n (%) 138 (34.9) 88 (29.7) 50 (50.5)
24–60 months, n (%) 100 (25.3) 65 (22.0) 35 (35.4)
> 60 months, n (%) 157 (39.8) 143 (48.3) 14 (14.1)
SBP (mmHg), mean ± SD 121.2 ± 18.9 121.8 ± 19.7 112.6 ± 14.3****
DBP (mmHg), mean ± SD 77.4 ± 10.4 78.8 ± 9.9 71.6 ± 8.6****
Comparisons reserved for HAART-exposed versus HAART-naïve patients
Abbreviations: BMI body mass index, DBP diastolic blood pressure, HAART highly active antiretroviral therapy, n number, SBP systolic blood pressure, SD standard
deviation, WC waist circumference
*P < 0.05
**P = 0.0001
***P < 0.01
****P < 0.00001
Table 2 Linear regression models of blood pressure on BMI and WC stratified by HAART status
HAART-exposed HAART-naive Overall
Systolic BP Diastolic BP Systolic BP Diastolic BP Systolic BP Diastolic BP
BMI 1.10 (0.60 to 1.61) 0.55 (0.29 to 0.80) 1.13 (0.50 to 1.75) 0.88 (0.52 to 1.23) 1.20 (0.79 to 1.62) 0.70 (0.48 to 0.92)
P < 0.0001 P < 0.0001 P = 0.001 P < 0.0001 P < 0.0001 P < 0.0001
WC 0.36 (0.15 to 0.58) 0.23 (0.12 to 0.34) 0.46 (0.24 to 0.68) 0.31 (0.18 to 0.44) 0.44 (0.28 to 0.61) 0.29 (0.20 to 0.38)
P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
Abbreviations: BMI body mass index, BP blood pressure, WC waist circumference
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Unadjusted mediating effects of body fat measures on
the association between HAART and blood pressure
Table 3 presents the unadjusted mediating effects of
body mass index and waist circumference on the associ-
ations of HAART with increasing systolic and diastolic
blood pressure. The indirect effects (Path AB) through
body mass index were statistically significant in the asso-
ciations of HAART with increasing systolic (coefficient
of indirect effect: 1.29, 95 % CI: 0.37 to 2.70) and dia-
stolic blood pressure (coefficient: 0.73, 95 % CI: 1.01 to
1.35), mediating 14 % and 10 % respectively of the total
effects of HAART on systolic and diastolic blood pres-
sure. Waist circumference mediated 15 % (coefficient:
1.35, 95 % CI: 0.24 to 2.76) and 12 % (coefficient: 0.87,
95 % CI: 0.17 to 1.69) of the total effects of HAART on
systolic and diastolic blood pressure respectively. Com-
bined body mass index/waist circumference accounted
for 16 % (coefficient: 1.51, 95 % CI: 0.28 to 3.15) and
12 % (coefficient: 0.95, 95 % CI: 0.19 to 2.24) of the total
effects of HAART on systolic and diastolic blood pres-
sure levels, respectively.
Covariate-adjusted mediating effects of body fat
measures on the association between HAART and blood
pressure
Table 4 summarizes the covariate-adjusted mediating
effects of body mass index and waist circumference on
the associations of HAART with increasing systolic and
diastolic blood pressure. After adjusting for age, sex and
smoking status, body mass index remained a significant
mediator of the total effects of HAART on systolic (coef-
ficient: 1.24, 95 % CI: 0.21 to 2.69, 13 % mediated) and
diastolic blood pressure (coefficient: 0.68, 95 % CI: 0.30
to 1.52, 9 % mediated). Waist circumference also
remained a significant partial mediator of the total
effects of HAART on systolic blood pressure (coefficient:
1.07, 95 % CI: 0.16 to 2.74, 12 % mediated) and diastolic
blood pressure (coefficient: 0.71, 95 % CI: 0.12 to 1.65,
10 % mediated) after adjusting for age, sex and smoking
status. Similarly, the combination of body mass index
with waist circumference mediated 15 % (coefficient:
1.40, 95 % CI: 0.33 to 3.01) and 11 % (coefficient: 0.88,
95 % CI: 0.26 to 1.84) of the total effects of HAART on
systolic blood pressure and diastolic blood pressure re-
spectively, after adjusting for age, sex and smoking sta-
tus. However, while the mediating effects of body mass
index and combined body mass index/waist circumfer-
ence were attenuated by additional confounders, includ-
ing CD4 cell count and duration of HIV infection, we
observed that the mediating effects of waist circumfer-
ence remained statistically significant, accounting for
11 % (coefficient: 1.01, 95 % CI: 0.33 to 2.52) and 9 %
(coefficient: 0.68, 95 % CI: 0.26 to 1.89) of the total ef-
fects of HAART on systolic blood pressure and diastolic
blood pressure, respectively.
Discussion
The main finding of this study of a sample of HIV-
infected adults emphasizes the stronger impact of cen-
tral fat distribution (measured by waist circumference),
compared with relative weight (measured by body mass
index), in mediating the associations of HAART with in-
creased systolic and diastolic blood pressure, independ-
ent of factors that could attenuate these associations,
such as age, sex, smoking status, CD4 cell count and
duration of HIV infection. This finding is consistent with
a large body of scientific evidence on the predominant
role of central adiposity, as opposed to relative weight,
in the aetiology of cardio-metabolic disorders [22–25].
We assert that the pathophysiological mechanisms to
Table 3 Unadjusted mediating effects of BMI and WC on the association between HAART and blood pressure (N = 406)
Mediator variable Predictor
variable
Outcome
variable
Path A Path B Path C’ Path AB %
mediatedCoefficient (95 % CI) Coefficient (95 % CI) Coefficient (95 % CI) Coefficient (95 % CI)
BMI HAART Systolic BP 1.16 (0.16 to 2.16) 1.11 (0.70 to 1.52) 8.28 (4.15 to 12.41) 1.29 (0.37 to 2.70) 14
Diastolic BP 1.16 (0.16 to 2.16) 0.62 (0.42 to 0.83) 6.77 (4.65 to 8.88) 0.73 (1.01 to 1.35) 10
WC HAART Systolic BP 3.42 (0.92 to 5.92) 0.39 (0.23 to 0.56) 7.96 (3.86 to 12.06) 1.35 (0.24 to 2.76) 15
Diastolic BP 3.42 (0.92 to 5.92) 0.26 (0.17 to 0.34) 6.71 (4.60 to 8.81) 0.87 (0.17 to 1.69) 12
Combined BMI/WC HAART Systolic BP 4.36 (0.85 to 7.89) 1.01 (0.24 to 1.78) 8.15 (4.08 to 12.23) 1.51 (0.28 to 3.15) 16
Diastolic BP 4.36 (0.85 to 7.89) 0.54 (0.15 to 0.94) 6.87 (4.79 to 8.95) 0.95 (0.19 to 2.24) 12
Path A – regression coefficient for the independent variable when the mediator variable is regressed on the independent variable
Path B – regression coefficient for the mediator variable when the dependent variable is regressed on the mediator variable, adjusted for the
independent variable
Path C – the direct effect of the independent variable on the dependent variable
Path AB – the indirect effect of the independent variable on the dependent variable through the mediator variable
% mediated – the amount (in percentage) of the total effect of the independent variable on the dependent variable that is attributed indirectly to the
mediator variable
NS – not statistically significant at 5 % level; all other coefficients were statistically significant
95 % confidence intervals for indirect effects (Path AB) are bias-corrected
Abbreviations: BMI body mass index, CI confidence interval, HAART highly active antiretroviral therapy, WC waist circumference
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account for the differential mediating effects of body
mass index and waist circumference reside mainly in the
relatively limited utility of body mass index, compared
with waist circumference, in detecting important cardio-
metabolic changes driven by central fat accumulation
[23–25]. The associations between body fat measures
and blood pressure did not differ significantly between
HAART-exposed and HAART-naïve patients, suggesting
that HAART status may not be an effect modifier of
these associations, further affirming the potential super-
iority of mediation modelling over effect-modification in
developing alternative causal hypotheses for high blood
pressure (and its complications) in persons living with
HIV. Nonetheless, while the chronic inflammatory and
platelet-activating effects of HIV infection ― known
mechanisms that underlie blood pressure changes in
antiretroviral-naïve HIV-infected patients ― corroborate
this finding [26], we cannot rule out the possibility that
the stratified analyses may not have been adequately
powered to detect effect modification, given the rela-
tively small sample size of HAART-naïve patients [27].
We observed that slightly higher proportions of the
total effects of HAART on systolic and diastolic blood
pressure were mediated by the combined effects of body
mass index/waist circumference, as opposed to either
body mass index or waist circumference alone, after
adjusting for traditional risk factors individually (age, sex
and smoking status). Previous evidence asserting that
the combined measure of body mass index and waist cir-
cumference better predicts hypertension, compared with
either body mass index or waist circumference, broadly
corroborate this finding [28, 29].
The results of our study may have important clinical
and public health implications. For instance, interventions
aimed at weight management may be effective for blood
pressure control among HIV-infected patients. Although
lifestyle factors may be limited in predicting hypertension
and other cardio-metabolic disorders in people living with
HIV on HAART [30], lifestyle interventions have been
shown to be effective in reducing blood pressure in this
high-risk subgroup [31]. In addition, the use of waist cir-
cumference as a complementary body fat measure to body
mass index may improve the clinical prediction of hyper-
tension among HIV-infected patients on antiretroviral
therapy. From a public health perspective, the prediction
and early detection of high blood pressure in people living
with HIV using measures of central fat distribution may
potentially strengthen the surveillance of hypertension
with its complications in people living with HIV, particu-
larly in sub-Saharan African settings where cardiovascular
conditions tend to be neglected in this high-risk popula-
tion [32–34].
While the mediating effects of body fat measures on
the association between HAART and increased blood
pressure may indicate a return to health, as opposed
to a pathological process, we speculate that this
phenomenon would only occur in HIV-infected pa-
tients in the advanced clinical stages of HIV infection
[35]. Such patients, who are likely to be antiretroviral-
naïve or resistant to antiretroviral treatment, also tend
to be underweight and hypotensive, such that the initi-
ation of HAART or antiretroviral switch therapy is
likely to improve body weight and blood pressure
levels, albeit transiently [35–37]. However, none of the
Table 4 Covariate-adjusted mediating effects of BMI and WC on the association between HAART and blood pressure
Mediator variable Predictor
variable
Outcome
variable
Path AB* %
mediated*
Path AB† %
mediated†
Path AB‡ %
mediated‡Coefficient (95 % CI) Coefficient (95 % CI) Coefficient (95 % CI)
BMI HAART Systolic BP 1.32 (0.30 to 2.62) 14 1.24 (0.21 to 2.69) 13 0.85 (−0.67 to 2.38)NS 9
Diastolic BP 0.74 (0.20 to 1.92) 10 0.68 (0.30 to 1.52) 9 0.45 (−0.40 to 1.27)NS 6
WC HAART Systolic BP 1.14 (0.21 to 3.19) 13 1.07 (0.16 to 2.74) 12 1.01 (0.33 to 2.52) 11
Diastolic BP 0.76 (0.16 to 1.44) 10 0.71 (0.12 to 1.65) 10 0.68 (0.26 to 1.89) 9
Combined BMI/WC HAART Systolic BP 1.40 (0.33 to 3.01) 15 1.40 (0.33 to 3.01) 15 1.00 (−0.40 to 3.63)NS 11
Diastolic BP 0.88 (0.26 to 1.84) 11 0.88 (0.26 to 1.84) 11 0.70 (−0.18 to 2.13)NS 9
Path AB* – the indirect effect of HAART on the outcome variable through the mediator variable, controlled for age (continuous) and sex
Path AB† − the indirect effect of HAART on the outcome variable through the mediator variable, controlled for age (continuous), sex and smoking status
Path AB‡ – the indirect effect of HAART on the outcome variable through the mediator variable, controlled for age (continuous), sex, smoking status, CD4 count
(continuous), and HIV duration
Coefficients for paths A, B and C’ are as shown in Table 3
% mediated* – proportion of the total effect of HAART on each outcome variable that is attributed indirectly to the mediator variable, adjusted for age and sex
% mediated† − proportion of the total effect of HAART on each outcome variable that is attributed indirectly to the mediator variable, adjusted for age, sex
and smoking
% mediated‡ – proportion of the total effect of the independent variable on the dependent variable that is attributed indirectly to the mediator variable, adjusted
for age, sex, smoking status, CD4 cell count and HIV duration
NS – not statistically significant at 5 % level; all other coefficients were statistically significant
95 % confidence intervals for indirect effects (Path AB) are bias-corrected
Abbreviations: BMI body mass index, BP systolic blood pressure, CI confidence interval, HAART highly active antiretroviral therapy, WC waist circumference
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participants in our study presented with an AIDS-
defining illness or were determined to be resistant to
antiretroviral treatment, as specified in the exclusion
criteria for participants deemed ineligible for inclusion
in this study.
Strengths and limitations
Our findings must be interpreted with caution, given the
observational nature of our study which precluded any
causal inferences. In addition, the potential for residual
confounding and bias is high in cross-sectional studies.
The present study was set in semi-urban Nigeria, which
may limit the generalizability of our findings to HIV-
infected populations from rural settings or outside of the
sub-Saharan African region. For instance, while reverse
transcriptase inhibitors are the mainstay of antiretroviral
therapy in sub-Saharan African countries [32–34], prote-
ase inhibitors are the drugs of choice for initiating anti-
retroviral treatment among people living with HIV
across European countries and the Americas [38]. More-
over, we speculate that different classes of antiretroviral
drugs may confer differential effects on body fat mea-
sures and blood pressure. We did not assess the poten-
tial influence of diet and physical activity on the impact
of body mass index and waist circumference in mediat-
ing the effects of HAART on blood pressure; however,
lifestyle factors may be of limited value in predicting
cardio-metabolic risk in people living with HIV on
HAART [30]. In addition, the potential for recall bias in
obtaining dietary data and self-reported physical activity
is particularly high. Lastly, we could not assess the po-
tential mediating roles of more sensitive measures of
adiposity (such as fat mass) on the effects of HAART on
blood pressure. The assessment of body fat mass entails
the use of sophisticated and costly investigative tech-
niques, including dual energy x-ray absorptiometry
(DEXA) and bioelectrical impedance analysis [39], which
are often not feasible in sub-Saharan African settings,
given the existing resource constraints.
Despite these limitations, our study presents important
strengths. For instance, we present the first evidence of
an alternative causal pathway to explain the effects of
HAART exposure on blood pressure: the independent
mediating role of waist circumference on the effects of
HAART on systolic and diastolic blood pressure is a
novel finding of the present study. Although blood pres-
sure was not prospectively measured upon the initiation
of HAART, we affirm that the mediation models pre-
sented in this study account for the direction of associ-
ation, which favours the hypothesis that HAART
influences changes in body fat measures, which in turn
influence changes in blood pressure. It would seem bio-
logically less plausible if the reverse (or any other kind
of interaction) was the case. Secondly, the exclusion of
patients in the advanced stages of HIV-infection from
the study does not allow for an alternative interpretation
of the findings, for instance, the impact of body mass
index and waist circumference in mediating the effects
of HAART on systolic and diastolic blood pressure are
more likely to be pathological than indicative of a
physiological return to health. Thirdly, the inclusion of
important covariates as potential confounders in the me-
diation analyses ensures that estimates of the mediation
effects are less likely to be exaggerated. Lastly, boot-
strapping with bias-corrected 95 % confidence intervals
was the preferred alternative to the Sobel-Goodman me-
diation test in ascertaining the statistical significance of
the mediating effects. Unlike the latter, bootstrapping is
not affected by sample size; hence, our relatively small-
sized study is unlikely to produce inaccurate estimates of
indirect effects [40, 41]. In addition, the bias-corrected
95 % confidence intervals for the indirect effects corrects
for potential skewedness in the data [19, 20].
Conclusions
In conclusion, waist circumference partially mediates the
effects of HAART on systolic and diastolic blood pressure,
independent of covariates that could potentially attenuate
these associations. Whether or not these associations are
consistent in prospective analyses should be investigated
by future studies.
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